These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 32733900)

  • 21. Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease.
    Majumder S; Mohapatra S; Lennon RJ; Piovezani Ramos G; Postier N; Gleeson FC; Levy MJ; Pearson RK; Petersen BT; Vege SS; Chari ST; Topazian MD; Witzig TE
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1947-1953. PubMed ID: 29526692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of clinical features and outcomes of proliferative, fibrotic, and mixed subtypes of IgG4-related disease: A retrospective cohort study.
    Peng L; Zhang X; Zhou J; Li J; Liu Z; Lu H; Peng Y; Fei Y; Zhao Y; Zeng X; Zhang W
    Chin Med J (Engl); 2024 Feb; 137(3):303-311. PubMed ID: 37538048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Comparison of Azathioprine and Mycophenolate Mofetil as Adjuvant Drugs in Patients with Pemphigus: A Retrospective Cohort Study.
    Sukanjanapong S; Thongtan D; Kanokrungsee S; Suchonwanit P; Chanprapaph K
    Dermatol Ther (Heidelb); 2020 Feb; 10(1):179-189. PubMed ID: 31865535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum IgG4 level during initial treatment as a predictor of relapse in IgG4-related disease.
    Choi SJ; Ahn SM; Oh JS; Hong S; Lee CK; Yoo B; Kim YG
    PLoS One; 2023; 18(3):e0282852. PubMed ID: 36893163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial.
    Peng L; Nie Y; Zhou J; Wu L; Chen X; Wang F; Li J; Peng Y; Lu H; Zhao L; Li M; Zhao Y; Zeng X; Fei Y; Zhang W
    Ann Rheum Dis; 2024 Apr; 83(5):651-660. PubMed ID: 38216319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advantages of an alternate-day glucocorticoid treatment strategy for the treatment of IgG4-related disease: A preliminary retrospective cohort study.
    Fukui S; Nakai T; Kawaai S; Ikeda Y; Suda M; Nomura A; Tamaki H; Kishimoto M; Ohde S; Okada M
    Medicine (Baltimore); 2022 Sep; 101(39):e30932. PubMed ID: 36181016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials.
    Namas R; Tashkin DP; Furst DE; Wilhalme H; Tseng CH; Roth MD; Kafaja S; Volkmann E; Clements PJ; Khanna D;
    Arthritis Care Res (Hoboken); 2018 Mar; 70(3):439-444. PubMed ID: 28544580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relapse predictors and serologically unstable condition of IgG4-related disease: a large Chinese cohort.
    Liu Y; Zeng Q; Zhu L; Gao J; Wang Z; Wang Z; Yang F; Wang K; Chen D; Xia C; Zhang S; Wang Y; Shen D; Yu G; Li ZG
    Rheumatology (Oxford); 2020 Aug; 59(8):2115-2123. PubMed ID: 32097488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients.
    Wang L; Zhang P; Wang M; Feng R; Lai Y; Peng L; Fei Y; Zhang X; Zhao Y; Zeng X; Zhang F; Zhang W
    Arthritis Res Ther; 2018 Apr; 20(1):65. PubMed ID: 29636109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coronary periarteritis and pericarditis are rare but distinct manifestations of heart involvement in IgG4-related disease: a retrospective cohort study.
    Hua T; Du J; Guo X; Peng L; Zhou J; Nie Y; Man D; Li M; Pan L; Zhang W
    Orphanet J Rare Dis; 2024 Jul; 19(1):266. PubMed ID: 39010060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
    Feng X; Gu F; Chen W; Liu Y; Wei H; Liu L; Yin S; Da Z; Sun L
    Chin Med J (Engl); 2014; 127(21):3718-23. PubMed ID: 25382325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of immunoglobulin G4-related sialadenitis: outcomes of glucocorticoid therapy combined with steroid-sparing agents.
    Hong X; Zhang YY; Li W; Liu YY; Wang Z; Chen Y; Gao Y; Sun ZP; Peng X; Su JZ; Cai ZG; Zhang L; He J; Ren LM; Yang HY; Li ZG; Yu GY
    Arthritis Res Ther; 2018 Jan; 20(1):12. PubMed ID: 29382364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes and predictive relapse factors of IgG4-related disease following treatment: a long-term cohort study.
    Peng Y; Li JQ; Zhang PP; Zhang X; Peng LY; Chen H; Zhou JX; Zhang SZ; Yang HX; Liu JJ; Guo HF; Li J; Zhang X; Zhao Y; Zeng XF; Zhang FC; Fei YY; Zhang W
    J Intern Med; 2019 Nov; 286(5):542-552. PubMed ID: 31121062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mycophenolate mofetil versus cyclophosphamide plus in patients with connective tissue disease-associated interstitial lung disease: Efficacy and safety analysis.
    Wang P; Zhang L; Guo Q; Zhao L; Hao Y
    Open Med (Wars); 2023; 18(1):20230838. PubMed ID: 38025531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Lupus; 2015 Dec; 24(14):1520-8. PubMed ID: 26162684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical profiles differ in IgG4-related disease with and without allergy: a large case-control study in China.
    Zhao Z; Liu Y; Bai M; Zeng Q; Wang Z; Chen D; Li Z; Su Y
    Clin Exp Rheumatol; 2023 Sep; 41(9):1808-1814. PubMed ID: 36826798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical features and relapse risks of IgG4-related ophthalmic disease: a single-center experience in China.
    Zhao Z; Mou D; Wang Z; Zeng Q; Wang Z; Xue J; Ren L; Liu Y; Su Y
    Arthritis Res Ther; 2021 Mar; 23(1):98. PubMed ID: 33789746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
    Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
    Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sex disparities in clinical characteristics and prognosis of immunoglobulin G4-related disease: a prospective study of 403 patients.
    Wang L; Zhang P; Zhang X; Lin W; Tang H; Li J; Wang M; Liu X; Fei Y; Chen H; Peng L; Zhang L; Lai Y; Zeng X; Li X; Xue H; Zhao Y; Zhang F; Zhang W
    Rheumatology (Oxford); 2019 May; 58(5):820-830. PubMed ID: 30561747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative efficacy and safety of tacrolimus, mycophenolate mofetil, azathioprine, and cyclophosphamide as maintenance therapy for lupus nephritis : A Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Z Rheumatol; 2017 Dec; 76(10):904-912. PubMed ID: 27638015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.